Sandoz Group
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
-
Market Cap
29.54 Bil.
P/E Ratio
32.92
Dividend Yield
1.38 %
Earnings per Share
1.88 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 68.28 G | 0 Units |
| PRICE DETERMINATION TIME | 06/03/2026 / 09:57:05 PM | |
| DAILY VOLUME (UNITS) | 30 | |
| DAILY HIGH / LOW | 69 | 68.12 |
| PREV. DAY'S PRICE | 68.32 | (06/02) |
| CHANGE DAY BEFORE | -0.04 | -0.06 % |
| 52 WEEK HIGH / LOW | (-) | (-) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 3.99 | 3.50 | 1.88 | 0.00 | 0.17 |
| DIVIDENDS PER SHARE | 1.16 | 0.94 | 0.86 | 0.63 | 0.46 |
| DIVIDEND YIELD IN % | - | - | 1.38 % | 1.61 % | 1.66 % |
| DIVIDEND GROWTH IN % | - | - | 35.76 % | 36.00 % | - |
| PRICE - EARNINGS RATIO | 18.02 | 20.58 | 32.92 | - | 168.07 |
| PRICE - BOOK RATIO | - | - | 3.37 | 2.16 | 1.60 |
| PRICE - SALES RATIO | - | - | 2.74 | 1.77 | 1.31 |
| PRICE - CASH FLOW RATIO | - | - | 19.08 | 27.92 | 35.87 |
Master Data
| WKN | A3ETYB |
| ISIN | CH1243598427 |
| SYMBOL | D8Y |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | SANDOZ GROUP AG SF -,05 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Swiss Franc |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 432.70 Mil. |
| MARKET CAPITALISATION | 29.54 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -4.15 % | 0.18 % | -6.03 % | - | - | - | - | - |
| HIGH | 72.46 | 75.24 | 75.34 | - | - | - | - | - |
| LOW | 68.12 | 67.96 | 63.12 | - | - | - | - | - |
Dividend
per share
Company profile
Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. It acquires, manages and sells investments and intellectual property in the healthcare and medical device industry and conducts all business at home and abroad. The firm can acquire, sell, debit and manage interests in other companies, intellectual property rights and real estate at home and abroad, as well as establish branches and subsidiaries at home and abroad. The company was founded on January 17, 2022 and is headquartered in Rotkreuz, Switzerland.
Structured products for Sandoz Group
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.